MCID: PLM035
MIFTS: 46

Pulmonary Eosinophilia malady

Categories: Respiratory diseases, Blood diseases

Aliases & Classifications for Pulmonary Eosinophilia

About this section

Aliases & Descriptions for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 11 49 13 67
 
Asthmatic Pulmonary Eosinophilia 67

Classifications:



External Ids:

Disease Ontology11 DOID:9498
ICD9CM31 518.3
MeSH38 D011657
ICD1029 J82

Summaries for Pulmonary Eosinophilia

About this section
MalaCards based summary: Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to loeffler syndrome and asthma, and has symptoms including hemoptysis An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways are Inflammatory Response Pathway and Innate Lymphoid Cell Differentiation Pathways. Affiliated tissues include lung, t cells and neutrophil, and related mouse phenotypes are respiratory system and hematopoietic system.

Related Diseases for Pulmonary Eosinophilia

About this section

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 154)
idRelated DiseaseScoreTop Affiliating Genes
1loeffler syndrome30.2CCL11, CSF2, EPX, IL13, IL4, IL5
2asthma26.6CCL11, CCL17, CCL5, CSF2, EPX, IL13
3eosinophilic pneumonia11.5
4chronic eosinophilic pneumonia11.4
5idiopathic acute eosinophilic pneumonia11.2
6eosinophilia10.7
7merkel cell carcinoma10.6IL5, RNASE3
8giant ganglionic hyperplasia10.5CCL11, IL5
9solitary cyst of breast10.5CCL11, IL5
10hypotrichosis simplex10.5IL5, RNASE3
11crustacean allergy10.5IL5, RNASE3
12granulomatous endometritis10.5IL5, RNASE3
13chronic mucocutaneous candidiasis10.5CCL5, RNASE3
14gonadal disease10.5CCL11, CCL5
15cytoplasmic body myopathy10.4IL13, IL5
16myositis fibrosa10.4IL4, IL5
17aortic arch interruption10.4IL13, IL5
18acute conjunctivitis10.4IL4, IL5
19gonococcal synovitis10.4IL4, IL5
20anterior dislocation of lens10.4CCL11, IL4
21retinal vascular disease10.4CCL11, IL4
22plantar nerve lesion10.4IL13, RNASE3
23benign fibrous mesothelioma10.4IL4, IL5
24winchester syndrome10.4EPX, RNASE3
25intracranial hypertension10.4CCL11, IL4
26indian tick typhus10.4CCL5, IL13
27acute interstitial pneumonia10.4CCL17, IL5
28african histoplasmosis10.3IL4, IL5
29cecum adenoma10.3EPX, RNASE3
30urinary bladder small cell neuroendocrine carcinoma10.3IL13, IL5
31primary orthostatic tremor10.3CCL5, IL4
32multiple system atrophy, cerebellar type10.3IL4, IL5
33goat milk allergy10.3IL13, IL4
34orbital lymphangioma10.3CCL5, IL4
35polyradiculoneuropathy10.3IL13, IL5
36motor peripheral neuropathy10.3EPX, IL4
37cow milk allergy10.3IL13, IL4
38philophthalmiasis10.3IL4, IL5
39abdominal tuberculosis10.3IL13, IL4
40keratoconjunctivitis10.2IL4, IL5, RNASE3
41chronic pulmonary heart disease10.2IL4, IL5, RNASE3
42thomsen and becker disease10.2IL4, IL5, RNASE3
43clostridium difficile colitis10.2EPX, RNASE3
44peanut allergy10.2IL4, IL5, RNASE3
45borst-jadassohn intraepidermal carcinoma10.2CCL11, RNASE3
46decubitus ulcer10.2CCL5, IL4
47subcorneal pustular dermatosis10.2IL4, IL5, RNASE3
48pediatric germ cell cancer10.2IL13, IL5
49papillary conjunctivitis10.2CCL11, IL4, RNASE3
50skin disease10.2IL13, IL5, RNASE3

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN):


Coronary Artery DiseaseDeficiency Anemia
Chronic Kidney FailureIschemic Heart Disease
Familial Atrial FibrillationRespiratory Failure
Schizophreniform DisorderHeart Disease
Iron Deficiency AnemiaProtein-Energy Malnutrition
EsophagitisPostinflammatory Pulmonary Fibrosis
Acute CystitisBronchitis
Active Peptic Ulcer DiseaseDecubitus Ulcer

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to pulmonary eosinophilia

Symptoms for Pulmonary Eosinophilia

About this section

UMLS symptoms related to Pulmonary Eosinophilia:


hemoptysis

Drugs & Therapeutics for Pulmonary Eosinophilia

About this section

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 108)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BudesonideapprovedPhase 442251333-22-363006, 5281004
Synonyms:
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC-4697
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
B 7777
B7777_SIGMA
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Bidien
Bio-0010
Budecort Inhaler
Budenofalk
Budeson
Budesonide (JAN/USAN/INN)
Budesonide Easyhaler
Budesonide MMX
Budesonide [USAN:INN:BAN:JAN]
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
CPD000058337
Cortivent
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
EU-0100174
Entocort
Entocort EC
Entocort EC (TN)
Giona Easyhaler
HMS1569H17
HMS1921I22
HMS2094I13
HMS501H17
Horacort
 
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
LS-187734
LS-7235
Lopac0_000174
MAP-0010
MLS000028507
MLS001077323
MLS002207112
Micronyl
Miflonide
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Prestwick_840
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort Turbuhaler
Pulmicort turbuhaler
Respules
Rhinocort
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort alpha
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S-1320
S1286_Selleck
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
ST51039033
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
budesonide
2
Nitric OxideapprovedPhase 4, Phase 259910102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
3
Omalizumabapproved, investigationalPhase 4143242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
4
MontelukastapprovedPhase 4266158966-92-85281040
Synonyms:
(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
(R-(e))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1e)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
151767-02-1 (sodium)
158966-92-8
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
AC1NQXXW
Apxi toxin
BIDD:GT0394
Brondilat
Brondilat (TN)
C07482
C35H36ClNO3S
CHEBI:50730
CHEMBL787
CID5281040
 
D08229
DB00471
HMS2089D07
HSDB 7582
LS-173539
MK 0476
MK-0476
Montair
Montelukast
Montelukast (INN)
Montelukast [INN:BAN]
Montelukastum
Montélukast
Singulair
Singular
UNII-MHM278SD3E
montelukast
sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
5
Prednisoloneapproved, vet_approvedPhase 4, Phase 3115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
6
Ciclesonideapproved, investigationalPhase 474126544-47-6, 141845-82-1444033
Synonyms:
(R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
126544-47-6
141845-82-1
AC-1330
Alvesco
Alvesco (TN)
Alvesco HFA
B-9207-015
BTR-15
BTR-15K
BY-9010
BYK-20426
CID6918155
Ciclesonide
 
Ciclesonide (JAN/USAN/INN)
Ciclesonide [INN]
D01703
KS-1165
LS-186047
MolPort-005-940-705
NCGC00167972-01
Omnair
Omnaris
Omnaris HFA
Osonase
Osonide
RPR 251526
TBN-15
UNII-S59502J185
7
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 3115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
8Leukotriene AntagonistsPhase 4291
9Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 312767
10Peripheral Nervous System AgentsPhase 4, Phase 222776
11ImmunoglobulinsPhase 4, Phase 3, Phase 26045
12HormonesPhase 4, Phase 2, Phase 313979
13Anti-Asthmatic AgentsPhase 4, Phase 23369
14Anti-Allergic AgentsPhase 4, Phase 21490
15Autonomic AgentsPhase 4, Phase 29774
16Hormone AntagonistsPhase 4, Phase 2, Phase 312778
17Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 310355
18Respiratory System AgentsPhase 4, Phase 24818
19Antibodies, MonoclonalPhase 4, Phase 3, Phase 23795
20glucocorticoidsPhase 4, Phase 2, Phase 34920
21AntibodiesPhase 4, Phase 3, Phase 26045
22Bronchodilator AgentsPhase 4, Phase 22856
23AlbuterolPhase 4, Phase 2408
24Adrenergic beta-AgonistsPhase 4, Phase 21640
25Neurotransmitter AgentsPhase 4, Phase 217734
26Adrenergic beta-2 Receptor AgonistsPhase 4, Phase 2925
27Dermatologic AgentsPhase 4, Phase 25674
28
Salmeterol xinafoatePhase 4, Phase 235094749-08-356801
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
 
GR-33343 G
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
SMR000875207
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent Inhaler and Disks
Serevent diskus
UNII-6EW8Q962A5
Ultrabeta
salmeterol xinafoate
29Adrenergic AgonistsPhase 4, Phase 22877
30Fluticasone Propionate, Salmeterol Xinafoate Drug CombinationPhase 4, Phase 2201
31
FluticasonePhase 4, Phase 263090566-53-3, 80474-14-262924, 22833648
Synonyms:
90566-53-3
AC-456
AC1NSJZT
Asmatil
Axotide
BIDD:GT0819
Brethal
C07815
CHEMBL1201396
CID5311101
Cultivate
Cutivate
D07981
Flixonase
Flixonase Nasal Spray
Flixotide
Flixotide Disk
 
Flixotide Disks
Flixotide Inhaler
Flonase
Flovent
Flovent Diskus
Flovent Rotadisk
Fluinol
Flunase
Flusonal
Fluspiral
Fluticaps
Fluticaps (TN)
Fluticasone (INN)
Fluticasonpropionat Allen
Flutide
Flutivate
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
fluticasone
32AntioxidantsPhase 4, Phase 2, Phase 12928
33Tocolytic AgentsPhase 4, Phase 2708
34Prednisolone acetatePhase 4, Phase 31153
35Methylprednisolone HemisuccinatePhase 4, Phase 31153
36Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 35407
37Methylprednisolone acetatePhase 4, Phase 31153
38Gastrointestinal AgentsPhase 48109
39Adrenergic AgentsPhase 4, Phase 25140
40Neuroprotective AgentsPhase 41672
41Prednisolone phosphatePhase 4, Phase 31153
42Protective AgentsPhase 4, Phase 2, Phase 17190
43Immunoglobulin EPhase 435
44Prednisolone hemisuccinatePhase 4, Phase 31153
45AntiemeticsPhase 43888
46Vasodilator AgentsPhase 43438
47Tiotropium BromidePhase 4324136310-93-5
48ParasympatholyticsPhase 41050
49Cholinergic AntagonistsPhase 41658
50BromidesPhase 4606

Interventional clinical trials:

(show top 50)    (show all 61)
idNameStatusNCT IDPhase
1Effect of Xolair on Airway HyperresponsivenessUnknown statusNCT00208234Phase 4
2Efficacy and Safety of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic BronchitisUnknown statusNCT01121016Phase 4
3The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic PneumoniaCompletedNCT00632554Phase 4
4Small Particle Steroids in Refractory AsthmaCompletedNCT01171365Phase 4
5Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsCompletedNCT00670930Phase 4
6Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsActive, not recruitingNCT02654145Phase 4
7Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMAActive, not recruitingNCT02546349Phase 4
8An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway InflammationNot yet recruitingNCT02937168Phase 4
9Mepolizumab Treatment for Rhinovirus-induced Asthma ExacerbationsUnknown statusNCT01520051Phase 3
10A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaCompletedNCT01285323Phase 3
11A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01270464Phase 3
12A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01287039Phase 3
13Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma ControlCompletedNCT02281318Phase 3
14Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaCompletedNCT01508936Phase 3
15Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)CompletedNCT00647166Phase 3
16Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma PatientsRecruitingNCT02555371Phase 3
17Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.RecruitingNCT02563067Phase 3
18Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.RecruitingNCT02555683Phase 3
19Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY StudyActive, not recruitingNCT02594332Phase 3
20A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic SubjectsActive, not recruitingNCT02135692Phase 3
21Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic AsthmaEnrolling by invitationNCT02559791Phase 2, Phase 3
22Study of Mepolizumab Safety Syringe in AsthmaticsNot yet recruitingNCT03021304Phase 3
23Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)Not yet recruitingNCT02836496Phase 3
24Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaTerminatedNCT01290887Phase 3
25A Phase IIa Study of KHK4563CompletedNCT01412736Phase 2
26Efficacy, Safety, and Tolerability of SAR231893 (REGN668) in Patients With Persistent Moderate to Severe Eosinophilic AsthmaCompletedNCT01312961Phase 2
27A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01227278Phase 2
28Anti-Interleukin-5 Antibody to Treat Hypereosinophilic SyndromeCompletedNCT00017862Phase 2
29Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)CompletedNCT00086658Phase 2
30OC000459 Bronchial Allergen ChallengeCompletedNCT01056692Phase 2
31Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic SubjectsCompletedNCT01057927Phase 2
32Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent AsthmaCompletedNCT01545726Phase 2
33Oral GW766944 (Oral CCR3 Antagonist)CompletedNCT01160224Phase 2
34The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)CompletedNCT00292877Phase 2
35A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)CompletedNCT00535028Phase 2
36Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
37Effect of OC000459 on Eosinophilic Airway Inflammation in Severe AsthmaRecruitingNCT02560610Phase 2
38Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic SyndromeRecruitingNCT02130882Phase 2
39Effect of OC459 on the Response to Rhinovirus Challenge in AsthmaRecruitingNCT02660489Phase 2
40Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in ChildrenActive, not recruitingNCT02377427Phase 2
41Investigation of Lung Ventilation Inhomogeneity in Pediatric AsthmaActive, not recruitingNCT01095354Phase 2
42Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic SyndromeActive, not recruitingNCT02101138Phase 2
43Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol SupplementsCompletedNCT00466596Phase 1
44Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
45Sirolimus for Eosinophil-Associated Gastrointestinal DisordersTerminatedNCT01814059Phase 1
46Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial PneumoniaUnknown statusNCT01152424
47The Factors Associated With the Formation of Nasal polyp-a Case Control and Descriptive StudyUnknown statusNCT01278719
48Clinico-biological Correlation of Severe Asthma in ChildrenUnknown statusNCT02038374
49Modification of Asthma With Soy IsoflavoneCompletedNCT00741208
50European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and BiobankRecruitingNCT02852928

Search NIH Clinical Center for Pulmonary Eosinophilia

Genetic Tests for Pulmonary Eosinophilia

About this section

Anatomical Context for Pulmonary Eosinophilia

About this section

MalaCards organs/tissues related to Pulmonary Eosinophilia:

35
Lung, T cells, Neutrophil, Bone, Testes, Bone marrow, Heart

Animal Models for Pulmonary Eosinophilia or affiliated genes

About this section

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.5CCL11, CSF2, IL13, IL4, IL5
2MP:00053977.7CCL11, CCL17, CCL5, CSF2, EPX, IL13
3MP:00053877.6CCL11, CCL17, CCL5, CSF2, EPX, IL13

Publications for Pulmonary Eosinophilia

About this section

Articles related to Pulmonary Eosinophilia:

(show top 50)    (show all 288)
idTitleAuthorsYear
1
Host lung immunity is severely compromised during tropical pulmonary eosinophilia: role of lung eosinophils and macrophages. (26489428)
2015
2
A rare presentation of hydropneumothorax in tropical pulmonary eosinophilia: cavitation and pneumonic consolidation in a child. (26376823)
2015
3
An Unusual Case of Foreign Body Aspiration Masquerading as Pulmonary Eosinophilia. (26266154)
2015
4
A rare case of ethambutol induced pulmonary eosinophilia. (24250213)
2013
5
Acquired alpha 1-antitrypsin deficiency in tropical pulmonary eosinophilia. (21808138)
2011
6
Pulmonary eosinophilia. (18197481)
2008
7
Death receptor-6 regulates the development of pulmonary eosinophilia and airway inflammation in a mouse model of asthma. (16730379)
2006
8
Parasitic pulmonary eosinophilia. (16612768)
2006
9
Simple pulmonary eosinophilia evaluated by means of FDG PET: the findings of 14 cases. (16374077)
2005
10
Tachykinin NK3-receptor deficiency does not inhibit pulmonary eosinophilia in allergic mice. (15501700)
2004
11
Clinical findings, bronchoalveolar lavage fluid cytology and matrix metalloproteinase-2 and -9 in canine pulmonary eosinophilia. (12093192)
2002
12
Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists. (11961081)
2002
13
CC chemokine receptor-2 is not essential for the development of antigen-induced pulmonary eosinophilia and airway hyperresponsiveness. (11086100)
2000
14
Differential susceptibility of C57BL/6 and DBA/2 mice to ovalbumin-induced pulmonary eosinophilia regulated by Th1/Th2-type cytokines. (10569702)
1999
15
Pulmonary eosinophilia associated with montelukast. (10335014)
1999
16
Re-examination of the diagnostic criteria of tropical pulmonary eosinophilia. (10542980)
1999
17
Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge. (10559323)
1999
18
C57BL/6 mice are more susceptible to antigen-induced pulmonary eosinophilia than BALB/c mice, irrespective of systemic T helper 1/T helper 2 responses. (10583592)
1999
19
Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. (9802959)
1998
20
Characterization of the antigen-presenting cell and T cell requirements for induction of pulmonary eosinophilia in a murine model of asthma. (8938110)
1996
21
Detection of living adult Wuchereria bancrofti in a patient with tropical pulmonary eosinophilia. (9181082)
1996
22
Minocycline and pulmonary eosinophilia. (7787604)
1995
23
Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. (8820246)
1995
24
Mast cells modulate allergic pulmonary eosinophilia in mice. (7695919)
1995
25
Atypical radiological presentation of tropical pulmonary eosinophilia. (7959950)
1994
26
Pulmonary eosinophilia with systemic features: therapy and prognosis. (1470705)
1992
27
Intratracheal application of Sephadex in rats leads to massive pulmonary eosinophilia without bronchial hyperreactivity to acetylcholine. (1382750)
1992
28
Rash and pulmonary eosinophilia associated with fenbufen. (2137356)
1990
29
Diminished translucency, a common roentgenographic feature of tropical pulmonary eosinophilia. (2924640)
1989
30
Pulmonary eosinophilia with and without allergic bronchopulmonary aspergillosis. (2595632)
1989
31
Airway hyperreactivity in tropical pulmonary eosinophilia. (3359833)
1988
32
Persisting "asthma" in tropical pulmonary eosinophilia. (6740545)
1984
33
Tropical pulmonary eosinophilia: an unusual presentation. (6618529)
1983
34
Lipodystrophy and pulmonary eosinophilia. (7228604)
1981
35
Pulmonary eosinophilia in a patient receiving beclomethasone dipropionate aerosol. (453651)
1979
36
Clinical studies in pulmonary eosinophilia. II--Relation of blood eosinophilia and pulmonary manifestations in clinic patients and urban population. (721166)
1978
37
Pulmonary eosinophilia. Part I. (730702)
1978
38
Adrenaline and tropical pulmonary eosinophilia. (1248889)
1976
39
Drug-induced lung disease: pulmonary eosinophilia and sulphonamides. (1236549)
1975
40
A study of parasites in domestic pests in households of patients with tropical pulmonary eosinophilia. (2551)
1975
41
Leukocyte adhesion phenomenon in pulmonary eosinophilia (tropical eosinophilia). (4683591)
1973
42
Asthma, pulmonary eosinophilia, and allergic alveolitis. (4633728)
1973
43
PRELIMINARY STUDIES ON THE PRODUCTION OF EXPERIMENTAL PULMONARY EOSINOPHILIA BY TISSUE ANTIGEN ANTIBODY REACTION OF THE HOST. (14235491)
1964
44
PULMONARY EOSINOPHILIA--TREATMENT WITH PARENTERAL DIETHYL-CARBAMAZINE. (14109682)
1963
45
Metaplastic cells in sputum of patients with pulmonary eosinophilia. (13647655)
1959
46
Tropical pulmonary eosinophilia. (13612472)
1958
47
Prolonged pulmonary eosinophilia; a report on three cases. (14363706)
1955
48
Clinical observations related to pulmonary eosinophilia. (13235631)
1955
49
Myelitis following arsenic therapy in pulmonary eosinophilia. (13017551)
1952
50
Pulmonary eosinophilia (tropical eosinophilia). (18152220)
1949

Variations for Pulmonary Eosinophilia

About this section

Expression for genes affiliated with Pulmonary Eosinophilia

About this section
Search GEO for disease gene expression data for Pulmonary Eosinophilia.

Pathways for genes affiliated with Pulmonary Eosinophilia

About this section

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 23)
idSuper pathwaysScoreTop Affiliating Genes
19.8IL4, IL5
29.4IL13, IL4, IL5
3
Show member pathways
9.4IL13, IL4, IL5
49.4IL13, IL4, IL5
59.4IL13, IL4, IL5
69.3CSF2, IL4, IL5
7
Show member pathways
9.3CSF2, IL4, IL5
89.3CSF2, IL4, IL5
98.9CSF2, IL13, IL4, IL5
108.9CSF2, IL13, IL4, IL5
11
Show member pathways
8.9CSF2, IL13, IL4, IL5
12
Show member pathways
8.9CCL11, CCL5, CCL7
138.8CCL11, CCL17, IL4, IL5
148.4CCL11, CCL17, IL13, IL4, IL5
15
Show member pathways
8.2CCL11, CCL17, CCL5, CCL7
16
Show member pathways
8.2CCL11, EPX, IL13, IL4, IL5, RNASE3
17
Show member pathways
7.1CCL11, CCL17, CCL5, CCL7, IL13, IL4
18
Show member pathways
7.1CCL11, CCL17, CCL5, CCL7, IL13, IL4
19
Show member pathways
6.6CCL11, CCL17, CCL5, CCL7, CSF2, IL13
20
Show member pathways
6.6CCL11, CCL17, CCL5, CCL7, CSF2, IL13
216.6CCL11, CCL17, CCL5, CCL7, CSF2, IL13
22
Show member pathways
6.6CCL11, CCL17, CCL5, CCL7, CSF2, IL13
23
Show member pathways
6.6CCL11, CCL17, CCL5, CCL7, CSF2, IL13

GO Terms for genes affiliated with Pulmonary Eosinophilia

About this section

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055766.4CCL11, CCL17, CCL5, CCL7, CSF2, IL13
2extracellular spaceGO:00056156.3CCL11, CCL17, CCL5, CCL7, CSF2, IL13

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 34)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of complement-dependent cytotoxicityGO:190366010.4IL13, IL4
2regulation of proton transportGO:001015510.4IL13, IL4
3positive regulation of mast cell degranulationGO:004330610.4IL13, IL4
4negative regulation of endothelial cell apoptotic processGO:200035210.4IL13, IL4
5positive regulation of immunoglobulin productionGO:000263910.3IL13, IL4
6microglial cell activationGO:000177410.3IL13, IL4
7positive regulation of podosome assemblyGO:007180310.2CSF2, IL5
8innate immune response in mucosaGO:000222710.2IL4, RNASE3
9chronic inflammatory responseGO:000254410.2CCL11, CCL5
10positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.2CSF2, IL4
11dendritic cell differentiationGO:009702810.2CSF2, IL4
12positive regulation of JAK-STAT cascadeGO:004642710.1CCL5, IL5
13positive regulation of B cell proliferationGO:003089010.0IL13, IL4, IL5
14myeloid dendritic cell differentiationGO:004301110.0CSF2, IL4
15positive regulation of natural killer cell chemotaxisGO:20005039.7CCL5, CCL7
16lymphocyte chemotaxisGO:00482479.6CCL11, CCL17, CCL5
17eosinophil chemotaxisGO:00482459.5CCL11, CCL5, CCL7
18positive regulation of inflammatory responseGO:00507299.4CCL11, CCL5, CCL7
19MAPK cascadeGO:00001659.4CCL5, CSF2, IL5
20cellular response to ethanolGO:00713619.2CCL5, CCL7
21immune responseGO:00069559.1CSF2, IL13, IL4, IL5
22cellular calcium ion homeostasisGO:00068748.9CCL11, CCL5, CCL7
23monocyte chemotaxisGO:00025488.8CCL11, CCL17, CCL5, CCL7
24cellular response to interleukin-1GO:00713478.8CCL11, CCL17, CCL5, CCL7
25positive regulation of cell migrationGO:00303358.8CCL11, CCL5, CCL7
26cellular response to interferon-gammaGO:00713468.7CCL11, CCL17, CCL5, CCL7
27neutrophil chemotaxisGO:00305938.7CCL11, CCL17, CCL5, CCL7
28cellular response to tumor necrosis factorGO:00713568.7CCL11, CCL17, CCL5, CCL7
29chemokine-mediated signaling pathwayGO:00700988.6CCL11, CCL17, CCL5, CCL7
30cell-cell signalingGO:00072678.6CCL17, CCL5, CCL7, IL13
31chemotaxisGO:00069358.2CCL11, CCL17, CCL5, CCL7, IL4
32positive regulation of ERK1 and ERK2 cascadeGO:00703747.9CCL11, CCL17, CCL5, CCL7
33inflammatory responseGO:00069547.9CCL11, CCL17, CCL5, CCL7, IL13, IL5
34positive regulation of GTPase activityGO:00435477.5CCL11, CCL17, CCL5, CCL7, CSF2, IL5

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1CCR chemokine receptor bindingGO:00480209.9CCL11, CCL17
2CCR4 chemokine receptor bindingGO:00317299.9CCL17, CCL5
3CCR1 chemokine receptor bindingGO:00317269.7CCL5, CCL7
4growth factor activityGO:00080839.3CSF2, IL4, IL5
5cytokine activityGO:00051258.6CSF2, IL13, IL4, IL5
6chemokine activityGO:00080098.1CCL11, CCL17, CCL5, CCL7

Sources for Pulmonary Eosinophilia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet